Related Experiment Video
Updated: Apr 12, 2026
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
Published on: November 17, 2018
High-intensity statin therapy in patients with chronic kidney disease: a systematic review and meta-analysis
Yu-Ling Yan1, Bo Qiu1, Jing Wang1
1Department of Cardiology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Insights
High-intensity statin therapy significantly reduces stroke risk in chronic kidney disease (CKD) patients. However, its impact on mortality, heart attack, heart failure, and kidney function requires further investigation due to limited evidence.
Area of Science:
- Cardiology
- Nephrology
- Pharmacology
Background:
- Chronic kidney disease (CKD) is associated with increased cardiovascular risk.
- Statins are widely used to manage cardiovascular risk, but their optimal intensity in CKD patients is debated.
Purpose of the Study:
- To evaluate the efficacy and safety of high-intensity statin therapy in patients with chronic kidney disease (CKD).
Main Methods:
- Systematic review and meta-analysis of randomized controlled trials (RCTs).
- Included RCTs compared high-intensity statin therapy (atorvastatin 80 mg or rosuvastatin 20/40 mg) with moderate/mild statin treatment or placebo.
- Primary outcomes included all-cause mortality, stroke, myocardial infarction, and heart failure; secondary outcomes included lipid levels, renal function, and adverse events.
Main Results:
- Six RCTs involving 10,993 CKD patients were analyzed.
- High-intensity statin therapy significantly reduced stroke risk (RR 0.69, 95% CI 0.56 to 0.85).
- Evidence for reducing all-cause mortality, myocardial infarction, and heart failure was low and inconclusive.
- High-intensity statins effectively lowered LDL-C but showed no clear renal protection.
- Adverse event rates did not significantly differ, but data limitations prevent definitive safety conclusions.
Conclusions:
- High-intensity statin therapy demonstrates efficacy in reducing stroke risk among CKD patients.
- The effects on major adverse cardiovascular events (mortality, MI, heart failure) and renal protection remain uncertain.
- Further high-quality studies are necessary to definitively assess the safety and efficacy of high-intensity statins in this population.
Objective:
To evaluate the efficacy and safety of high-intensity statin therapy in patients with chronic kidney disease (CKD).
Design:
A systematic review and meta-analysis.
Data Sources:
Randomised controlled trials (RCTs) comparing high-intensity statin therapy (atorvastatin 80 mg or rosuvastatin 20/40 mg) with moderate/mild statin treatment or placebo were derived from the databases (PubMed, Embase, Ovid, the Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library, and ISI Web of Knowledge).
Outcome Measure:
Primary end points: clinical events (all-cause mortality, stroke, myocardial infarction and heart failure); secondary end points: serum lipid, renal function changes and adverse events.
Results:
A total of six RCTs with 10,993 adult patients with CKD were included. A significant decrease in stroke was observed in the high-intensity statin therapy group (RR 0.69, 95% CI 0.56 to 0.85). However, the roles of high-intensity statin in decreasing all-cause mortality (RR 0.85, 95% CI 0.67 to 1.09), myocardial infarction (RR 0.69, 95% CI 0.40 to 1.18) and heart failure (RR 0.73, 95% CI 0.48 to 1.13) remain unclear with low evidence. High-intensity statin also had obvious effects on lowering the LDL-C level but no clear effects on renal protection. Although pooled results showed no significant difference between the intervention and control groups in adverse event occurrences, it was still insufficient to put off the doubts that high-intensity statin might increase adverse events because of limited data sources and low quality evidences.
Conclusions:
High-intensity statin therapy could effectively reduce the risk of stroke in patients with CKD. However, its effects on all-cause mortality, myocardial infarction, heart failure and renal protection remain unclear. Moreover, it is hard to draw conclusions on the safety assessment of intensive statin treatment in this particular population. More studies are needed to credibly evaluate the effects of high-intensity statin therapy in patients with CKD.
Related Concept Videos
01:28Chronic Kidney Disease III: Interprofessional Care
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:25Chronic Kidney Disease I: Introduction
01:18Chronic Kidney Disease IV: Nursing Management
01:20Acute Kidney Injury V: Interprofessional Care
01:24Chronic Kidney Disease II: Clinical Manifestations